Real-World Patient Characteristics, Treatment Patterns, and Mutation Testing Patterns Among US Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations

被引：0
|
作者：
Jinghua He
Christopher D. Pericone
Julie Vanderpoel
机构：
[1] Janssen Scientific Affairs,
[2] LLC,undefined
来源：
Advances in Therapy | 2022年 / 39卷
关键词：
Biomarker testing; mutations; Exon 20 mutations; Immunotherapy; Next-generation sequencing; NSCLC; Treatment pathways; Tyrosine kinase inhibitors;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3347 / 3360
页数：13
相关论文
共 50 条
  • [31] Real-world treatment patterns for advanced squamons non-small cell Mug cancer in the US Medicare population
    Goyal, Ravi K.
    Able, Stephen L.
    Davis, Keith L.
    Brown, Jacqueline
    Li, Li
    Kaye, James A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [32] PATIENT CHARACTERISTICS, TREATMENT PATTERNS, AND FACTORS OF BIOMARKER TESTING AMONG PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) IN THE US, 2012-2020
    Yang, M.
    MacEwan, J. P.
    Honnold, R.
    McClain, M. R.
    O'Hara, R.
    Liu, F.
    Paik, P.
    VALUE IN HEALTH, 2023, 26 (06) : S28 - S28
  • [33] Real-World PD-L1 Testing Patterns for Patients with Advanced Non-Small Cell Lung Cancer in Greece
    Kokkotou, E.
    Charpidou, A.
    Papaspiliou, A.
    Stournara, L.
    Grammatikou, V.
    Ejzykowicz, F.
    Syrigos, K.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S660 - S660
  • [34] EMERGENT THERAPIES AND EGFR MUTATION TESTING IN NON-SMALL CELL LUNG CANCER: REAL-WORLD PRACTICES
    Chen, L.
    Herrington, J. D.
    Godley, P. J.
    Rao, A.
    Henderson, S. M.
    VALUE IN HEALTH, 2018, 21 : S41 - S41
  • [35] Real-World Treatment Patterns Among Resected Patients With Non-Small Cell Lung Cancer Receiving Adjuvant Atezolizumab
    Lee, Jay M.
    Ogale, Sarika
    Johnson, Ann
    Patel, Achal
    Albarmawi, Husam
    Lee, Janet S.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E43 - E43
  • [36] Multicenter real-world data of patients harboring rare mutations other than EGFR or ALK in advanced or metastatic non-small cell lung cancer
    Lee, Su Yeon
    Kim, Young Chul
    Lee, Kye Young
    Lee, Sung Yong
    Lee, Shin Yup
    Lee, Min Ki
    Lee, Jeong Eun
    Jang, Seung Hun
    Jang, Tae-Won
    Choi, Chang Min
    THORACIC CANCER, 2022, 13 (03) : 380 - 385
  • [37] Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated?
    Sacher, Adrian G.
    Le, Lisa W.
    Lau, Anthea
    Earle, Craig C.
    Leighl, Natasha B.
    CANCER, 2015, 121 (15) : 2562 - 2569
  • [38] EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China
    Xu, Jianlin
    Jin, Bo
    Chu, Tianqing
    Dong, Xue
    Yang, Haitang
    Zhang, Yanwei
    Wu, Dan
    Lou, Yuqing
    Zhang, Xueyan
    Wang, Huiming
    Han, Baohui
    LUNG CANCER, 2016, 96 : 87 - 92
  • [39] Biomarker Testing and Associated Treatment patterns in Advanced Non-Small Cell Lung Cancer in the US
    Last, M.
    Burlison, H.
    Chandrasekar, S.
    Wong, C. Hooi
    Bailey, H.
    Forshaw, C.
    Foley, G.
    Duncan, K.
    Krulewicz, S.
    Wiltshire, R.
    Thomaidou, D.
    Iadeluca, L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E26 - E26
  • [40] Biomarker testing and treatment patterns in US patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) harboring MET amplification
    Ryder, Alex
    Oksen, Dina
    Boutmy, Emmanuelle
    Wang, Yuexi
    Nisbett, Alnecia R.
    Stroh, Christopher
    Johne, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345